Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

58

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Prostate CancerProstate NeoplasmProstate AdenocarcinomaProstate Cancer MetastaticMetastatic Prostate Cancer
Interventions
DRUG

18F-DCFPyL-iPSMA

Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.

DRUG

68Ga-HBED-iPSMA

Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA

DIAGNOSTIC_TEST

PET/CT scan

The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed

Trial Locations (7)

10021

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER